| Celgene Corporation | 108.28 |
| Date/Time | 11/20 / 21:59 |
| Chg. / Chg.(%) | - / |
| Bid | 108.15 / 33 |
| Ask | 109.50 / 2 |
| Open | 107.90 |
| Previous Close | 108.20 |
| High | 108.58 |
| Low | 107.28 |
| Volume [USD] | 393,221,131.68 |
| Volume [Units] | 4,250,731 |
| Price fixings | 29459 |
| ISIN | US1510201049 |
| Security | CELG |
| Exchange | Cboe US |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 93.00 | ||
| SIX Swiss Ex.. | 89.40 | ||
| NASDAQ | 108.2400 | 191,230,586 | |
| Cboe US | 108.28 | 4,250,731 | |
| IEX | 108.30 | 1,222,357 | |
| London Inter.. | 107.94 | 826,453 | |
| Lang & Schwa.. | 97.370 |
News
- BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
07/02/2020 / 13:00 - GlobeNewswire - BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
07/02/2020 / 00:00 - GlobeNewswire - BeiGene Announces Appointment of Angus Grant as Chief Business Executive
07/01/2020 / 13:00 - GlobeNewswire - BeiGene Begins Commercializing XGEVA® (Denosumab) in China
07/01/2020 / 01:30 - GlobeNewswire - BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
06/22/2020 / 15:00 - GlobeNewswire
Real-time